NEW YORK , Jan. 29, 2021 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors who purchased AstraZeneca PLC's American Depositary Shares ("ADSs") (NASDAQ: AZN) between May 21, 2020 and November 20, 2020 (the "Class Period").
A complaint has been filed alleging that Defendants misrepresented and failed to disclose widespread flaws in the design and execution of AstraZeneca's clinical trials of its COVID-19 vaccine candidate (AZD1222), including that a substantial number of trial participants received half the designed dosage due to a manufacturing error.
On Nov. 23, 2020 , AstraZeneca announced an interim analysis of its trial, revealing that the Company used two different dosing regimens in two smaller scale trials. In one trial, patients received a half dose followed by a full dose (resulting in 90% efficacy). In the other, patients received two full doses (resulting in 62% efficacy). Further, the complaint alleges that AstraZeneca revealed that the half dosing regimen was the result of a manufacturing error discovered early in the trial process and not part of the original trial design.
Following this news, the price of AstraZeneca's ADSs declined by about 5% over three trading days to close at $52.60 per share.
If you are a member of the proposed Class, you may move the court no later than March 27, 2021 to serve as a lead plaintiff for the purported class. You need not seek to become a lead plaintiff in order to share in any possible recovery. If you would like to discuss the complaint or our investigation, please contact us by emailing pmayer@kaplanfox.com or by calling (646) 315-9003
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Kaplan Fox & Kilsheimer LLP, with offices in New York , San Francisco , Los Angeles , Chicago and New Jersey , has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com . If you have any questions about this Notice, your rights, or your interests, please contact:
Donald R. Hall
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York , New York 10022
(646) 315-9003
E-mail: dhall@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street , Suite 1560
Oakland, California 94612
(415) 772-4704
Fax: (415) 772-4707
E-mail: lking@kaplanfox.com
View original content: http://www.prnewswire.com/news-releases/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-301218410.html
SOURCE Kaplan Fox & Kilsheimer LLP